| 1 |
Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis [J]. JAMA, 1996, 275(19):1489-1494.
|
| 2 |
Perrin T, Descombes E, Cook S. Contrast-induced nephropathy in invasive cardiology [J]. Swiss Med Wkly, 2012, 142: w13608.
|
| 3 |
Kitajima K, Maeda T, Watanabe S, et al. Recent issues in contrastinduced nephropathy [J]. Int J Urol, 2011, 18(10): 686-690.
|
| 4 |
Lencioni R, Fattori R, Morana G, et al. Contrast-induced nephropathy in patients undergoing computed tomography(CONNECT) - a clinical problem in daily practice? A multicenter observational study [J]. Acta Radiol, 2010, 51(7): 741-750.
|
| 5 |
Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR)[J]. Eur Radiol, 1999, 9(8): 1602-1613.
|
| 6 |
Stacul F, van der Molen AJ, Reimer P, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines [J]. Eur Radiol, 2011, 21(12): 2527-2541.
|
| 7 |
Weisbord SD, Chen H, Stone RA, et al. Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography [J]. J Am Soc Nephrol, 2006, 17(10): 2871-2877.
|
| 8 |
Solomon RJ, Mehran R, Natarajan MK, et al. Contrast-induced nephropathy and long-term adverse events: cause and effect? [J].Clin J Am Soc Nephrol, 2009, 4(7): 1162-1169.
|
| 9 |
Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury [J]. Crit Care, 2007, 11(2): R31.
|
| 10 |
Waikar SS, Bonventre JV. Creatinine kinetics and the definition of acute kidney injury [J]. J Am Soc Nephrol, 2009, 20(3): 672-679.
|
| 11 |
Adiyanti SS , Loho T. Acute Kidney Injury (AKI) biomarker [J].Acta Med Indones, 2012, 44(3): 246-255.
|
| 12 |
Alharazy SM, Kong N, Saidin R, et al. Serum Neutrophil Gelatinase-Associated Lipocalin and Cystatin C are early Biomarkers of Contrast-Induced Nephropathy After Coronary Angiography in Patients With Chronic Kidney Disease [J].Angiology, 2013, Epub ahead of print.
|
| 13 |
Manabe K, Kamihata H, Motohiro M, et al. Urinary liver-type fatty acid-binding protein level as a predictive biomarker of contrast-induced acute kidney injury [J]. Eur J Clin Invest, 2012,42(5): 557-563.
|
| 14 |
Vaidya VS, Waikar SS, Ferguson MA, et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans [J]. Clin Transl Sci, 2008, 1(3): 200-208.
|
| 15 |
Haase M, Bellomo R, Devarajan P, et al. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and metaanalysis [J]. Am J Kidney Dis, 2009, 54(6): 1012-1024.
|
| 16 |
Briguori C, Visconti G, Rivera NV, et al. Cystatin C and contrastinduced acute kidney injury [J]. Circulation, 2010, 121(19): 2117-2122.
|
| 17 |
Vanmassenhove J, Vanholder R, Nagler E, et al. Urinary and serum biomarkers for the diagnosis of acute kidney injury: an indepth review of the literature [J]. Nephrol Dial Transplant, 2013,28(2): 254-273.
|
| 18 |
Rundback JH, Nahl D, Yoo V. Contrast-induced nephropathy [J].J Vasc Surg, 2011, 54(2): 575-579.
|
| 19 |
Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation [J]. J Am Coll Cardiol, 2004, 44(7): 1393-1399.
|
| 20 |
Brown JR, Malenka DJ, DeVries JT, et al. Transient and persistent renal dysfunction are predictors of survival after percutaneous coronary intervention: insights from the Dartmouth Dynamic Registry [J]. Catheter Cardiovasc Interv, 2008, 72(3): 347-354.
|
| 21 |
Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial.The Iohexol Cooperative Study [J]. Kidney Int, 1995, 47(1): 254-261.
|
| 22 |
Heinrich MC, Haberle L, Muller V, et al. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials [J].Radiology, 2009, 250(1): 68-86.
|
| 23 |
Alamartine E, Phayphet M, Thibaudin D, et al. Contrast mediuminduced acute renal failure and cholesterol embolism after radiological procedures: incidence, risk factors, and compliance with recommendations [J]. Eur J Intern Med, 2003, 14(7): 426-431.
|
| 24 |
Mitchell AM, Jones AE, Tumlin JA, et al. Incidence of contrastinduced nephropathy after contrast-enhanced computed tomography in the outpatient setting [J]. Clin J Am Soc Nephrol,2010, 5(1): 4-9.
|
| 25 |
Mueller C. Prevention of contrast-induced nephropathy with volume supplementation [J]. Kidney Int, 2006, Suppl 100: S16-S19.
|
| 26 |
Kunadian V, Zaman A, Spyridopoulos I, et al. Sodium bicarbonate for the prevention of contrast induced nephropathy: a metaanalysis of published clinical trials [J]. Eur J Radiol, 2011, 79(1):48-55.
|
| 27 |
Klima T, Christ A, Marana I, et al. Sodium chloride vs. sodium bicarbonate for the prevention of contrast medium-induced nephropathy: a randomized controlled trial[J]. Eur Heart J. 2012,33(16): 2071-2079.
|
| 28 |
Stacul F, Adam A, Becker CR, et al. Strategies to reduce the risk of contrast-induced nephropathy [J]. Am J Cardiol, 2006, 98(6A):59K-77K.
|
| 29 |
Kelly AM, Dwamena B, Cronin P, et al. Meta-analysis:effectiveness of drugs for preventing contrast-induced nephropathy [J]. Ann Intern Med, 2008, 148(4): 284-294.
|
| 30 |
Hoffmann U, Fischereder M, Kruger B, et al. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable [J]. J Am Soc Nephrol, 2004,15(2): 407-410.
|
| 31 |
Alioglu E, Saygi S, Turk U, et al. N-Acetylcysteine in Preventing Contrast-Induced Nephropathy Assessed by Cystatin C [J].Cardiovasc Ther, 2013, 31(3): 168-173.
|
| 32 |
Kini AS, Mitre CA, Kim M, et al. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam [J]. Catheter Cardiovasc Interv, 2002, 55(2): 169-173.
|
| 33 |
Weisz G, Filby SJ, Cohen MG, et al. Safety and performance of targeted renal therapy: the Be-RITe! Registry [J]. J Endovasc Ther, 2009, 16(1): 1-12.
|
| 34 |
Sharyo S, Yokota-Ikeda N, Mori M, et al. Pravastatin improves renal ischemia-reperfusion injury by inhibiting the mevalonate pathway [J]. Kidney Int, 2008, 74(5): 577-584.
|
| 35 |
Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions [J]. Am J Med, 2005, 118(8): 843-849.
|
| 36 |
Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention [J]. Am J Cardiol, 2008, 101(3): 279-285.
|
| 37 |
Jo SH, Koo BK, Park JS, et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial--a randomized controlled study [J]. Am Heart J, 2008, 155(3): 499 e491- e498.
|
| 38 |
Toso A, Maioli M, Leoncini M, et al. Usefulness of atorvastatin(80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease [J]. Am J Cardiol, 2010, 105(3): 288-292.
|
| 39 |
Sadat U. Contrast-induced nephropathy: do statins offer protection? [J]. Curr Opin Cardiol, 2011, 26(4): 334-337.
|
| 40 |
Zhang L, Lu Y, Wu B, et al. Efficacy of statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis of randomised controlled trials [J]. Int J Clin Pract, 2011, 65(5): 624-630.
|
| 41 |
Cruz DN, Goh CY, Marenzi G, et al. Renal replacement therapies for prevention of radiocontrast-induced nephropathy: a systematic review [J]. Am J Med, 2012, 125(1): 66-78 e63.
|
| 42 |
Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration [J]. N Engl J Med, 2003, 349(14): 1333-1340.
|